References
- Asaki T, Kuwano K, Morrison K, et al. (2015). Selexipag: an oral and selective IP prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. J Med Chem 58:7128–37.
- Kuwano K, Hashino A, Asaki T, et al. (2007). 2-[4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Ther 322:1181–8.
- Li B, Sedlacek M, Manoharan I, et al. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673–84.
- Nakamura A, Yamada T, Asaki T. (2007). Synthesis and evaluation of N-acylsulfonamide and N-acylsulfonylurea prodrugs of a prostacyclin receptor agonist. Bioorg Med Chem 15:7720–5.
- Scott LJ. (2016). Selexipag: first global approval. Drugs 76:413–8.
- Treiber A, Miraval T, Bolli MH, et al. (2016). The metabolism of the dual endothelin receptor antagonist macitentan in rat and dog. Xenobiotica 46:253–67.